20. Multiple Myeloma: Molecular Biology, Diagnosis and Treatment

  1. Hussain I. Saba MD, PHD2 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH3
  1. Shaji Kumar and
  2. S. Vincent Rajkumar

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch20

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

Kumar, S. and Rajkumar, S. V. (2011) Multiple Myeloma: Molecular Biology, Diagnosis and Treatment, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch20

Editor Information

  1. 2

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 3

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • plasma cell;
  • multiple myeloma;
  • genetics;
  • chromosomal translocations;
  • prognosis;
  • monoclonal protein;
  • immunoglobulins;
  • stem cell transplant;
  • immunomodulatory drugs;
  • proteasome inhibitors


Multiple myeloma represents malignant transformation of terminally differentiated plasma cells, and makes up 1% of all cancers and 10% of hematological malignancies with a male predominance and higher incidence in older patients. The disease remains incurable with current treatments and contributes to considerable morbidity and mortality among affected patients. The past decade has seen dramatic progress, both in our understanding of the molecular basis of the disease and in the development of new therapies for the disease. The high response rates seen with the new drugs, especially in combination, has led to a paradigm change in the approach to the patient with myeloma.